Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-term longitudinal, non interventional, observational, prospective study to collect in a real life setting data on the retention, effectiveness, safety, treatment pattern, quality of life, and efficiency of secukinumab in adult patients with moderate to severe plaque psoriasis, psoriatic arthritis or ankylosing spondylitis

Next Previous
Search
Trial Profile

Long-term longitudinal, non interventional, observational, prospective study to collect in a real life setting data on the retention, effectiveness, safety, treatment pattern, quality of life, and efficiency of secukinumab in adult patients with moderate to severe plaque psoriasis, psoriatic arthritis or ankylosing spondylitis

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Ankylosing spondylitis; Plaque psoriasis; Psoriatic arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SERENA
  • Sponsors Novartis Pharma A.G.

    • Most Recent Events

    • 14 Nov 2022 Interim Results(n=997) assessing the impact of weight and sex on SEC treatment persistence and treatment safety in pts with active PsA or AS from the SERENA study presented at the ACR Convergence 2022
    • 16 Sep 2022 Long-term results from an interim analysis of the SERENA study published in the Journal of the European Academy of Dermatology and Venereology
    • 04 Jun 2022 Results assessing long term effectiveness and safety in pts with active PsA or AS, presented at the 23rd Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top